DexCom assumed with Perform from Outperform at Oppenheimer

Oppenheimer downgraded DexCom (DXCM) to Perform from Outperform without a price target after assuming coverage of the name. The company is doing all it can to offset industry challenges but field checks indicate rising concerns about G7 accuracy and performance, the analyst tells investors in a research note. In addition, the firm believes Abbott’s (ABT) glucose-ketone dual analyte sensor and L3 pump integrations “complicate” DexCom’s share gains in type 1 diabetes.